Laurus Labs jumps 128% from March lows, hits high in weak market

Laurus Labs Shares Surge 128% Since March Low, Defying Market Trends

Laurus Labs has demonstrated remarkable resilience, with its share price soaring 128% since March, reaching a new high amidst a generally weak market.

Strong Performance Against Market Trends

Laurus Labs’ share price has shown impressive growth, particularly in the last six months, where it has risen 83% compared to a 5% decline in the BSE Sensex. The stock’s recent performance is notable, as it gained 1% on the BSE during Monday’s intraday trade, even as the broader market faced a downturn, with the Sensex down 0.44% at 74,398. Over the past three months, Laurus Labs has outperformed the market, with a 35% increase in its stock price, while the benchmark index saw a decline of 4.7%.

The stock’s ascent from its 52-week low of ₹913.35 on February 2, 2026, to its current high reflects strong investor confidence and positive market sentiment surrounding the company’s growth potential.

Upcoming Earnings and Analyst Expectations

Laurus Labs is set to announce its earnings for the September quarter (Q2FY27) on October 29, 2026. Analysts at Kotak Institutional Equities anticipate a robust performance, projecting an 86% year-on-year growth in Synthesis revenue to ₹880 crore. They expect overall API sales to grow by 11% year-on-year, driven by steady demand across various therapeutic areas, including anti-retroviral (ARV) and non-ARV APIs.

Furthermore, the brokerage forecasts a significant improvement in gross margins, expecting them to rise by 240 basis points year-on-year to 62.3%. Laurus Labs is also expected to report a 67% increase in EBITDA, reaching ₹680 crore, with a notable expansion in EBITDA margins.

CDMO Sector Growth and Laurus Labs’ Position

The Contract Development and Manufacturing Organization (CDMO) sector is experiencing robust growth, driven by increasing outsourcing and supply chain rebalancing among global pharmaceutical companies. According to India Ratings and Research, the sector has reported double-digit revenue growth in Q1FY27, indicating strong underlying demand despite some temporary challenges faced by certain companies.

Laurus Labs has positioned itself well within this expanding market, with its CDMO revenues showing remarkable growth. The company has increased its quarterly run rate from ₹220-250 crore to ₹800 crore over two years, reflecting a broad-based traction in its business. This growth is supported by a diverse client base and a focus on high-demand areas such as peptides and gene therapies.

Key Highlights

• Laurus Labs’ share price has surged 128% from its March low, reaching ₹2,087.
• The stock outperformed the BSE Sensex, which declined by 0.44% on the same day.
• Analysts expect Q2FY27 Synthesis revenue to grow 86% YoY to ₹880 crore.
• Overall API sales projected to increase by 11% YoY in Q2FY27.
• CDMO sector shows strong growth potential, expected to reach $22-25 billion by 2035.

Investor Note: The impressive rise in Laurus Labs’ share price, coupled with strong upcoming earnings expectations, positions the company favorably in the pharmaceutical sector. Investors should monitor the upcoming earnings report closely, as it could provide further insights into the company’s growth trajectory and market position.